Pharmacokinetic and pharmacodynamic bioequivalence between regular human insulin (rDNA origin) in 0.9% sodium chloride ready‐to‐use infusion 1 U/mL and 100 U/mL concentrate diluted to 1 U/mL in healthy males

To show pharmacokinetic (PK) and pharmacodynamic (PD) bioequivalence between Myxredlin, a novel, ready‐to‐use regular human insulin 1 U/mL formulation (BAX‐HI), and Novolin R 100 U/mL concentrate diluted to 1 U/mL (NOVO‐HI).

• Publication year

  2021

• Venue

  Diabetes, obesity and metabolism

• Publication date

  2021-08-10

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/dom.14520PMID 34378307PMCID 9290613
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• PreScription: Comments on the FDA Guidance "Compounded Drug Products That Are Essentially Copies of a Commercially Available Drug Product Under Section 503A of the Federal Food, Drug, and Cosmetic Act: Guidance for Industry".

  2022cited by this paper
• Review for "Pharmacokinetic and pharmacodynamic bioequivalence between regular human insulin ( rDNA origin) in 0.9% sodium chloride ready‐to‐use infusion 1 U / mL and 100 U / mL concentrate diluted to 1 U / mL in healthy males"

  2021cited by this paper
• Pharmacokinetic and pharmacodynamic bioequivalence between regular human insulin (rDNA origin) in 0.9% sodium chloride ready‐to‐use infusion 1 U/mL and 100 U/mL concentrate diluted to 1 U/mL in healthy males

  2021cited by this paper
• Pharmacokinetic and pharmacodynamic bioequivalence of proposed biosimilar MYL‐1501D with US and European insulin glargine formulations in patients with type 1 diabetes mellitus

  2019cited by this paper
• Assessment of final product dosing accuracy when using volumetric technique in the preparation of chemotherapy

  2016cited by this paper
• Insulin delivery methods: Past, present and future

  2016cited by this paper
• Prescribing Information

  2015cited by this paper
• Fluctuations of Hyperglycemia and Insulin Sensitivity Are Linked to Menstrual Cycle Phases in Women With T1D

  2015cited by this paper
• Low within- and between-day variability in exposure to new insulin glargine 300 U/ml

  2015cited by this paper
• Continuous Insulin Infusion: When, Where, and How?

  2014cited by this paper
• Potential Risks of Pharmacy Compounding

  2013cited by this paper
• Institute for Safe Medication Practices (ISMP)

  2013cited by this paper
• Insulin therapy for the management of hyperglycemia in hospitalized patients.

  2012cited by this paper
• Glycemic variability and glycemic control in the acutely ill cardiac patient.

  2012cited by this paper
• Standards of Medical Care in Diabetes—2012

  2011cited by this paper
• Pharmacokinetics and Pharmacodynamics of High-Dose Human Regular U-500 Insulin Versus Human Regular U-100 Insulin in Healthy Obese Subjects

  2011cited by this paper
• American Association of Clinical Endocrinologists and American Diabetes Association Consensus Statement on Inpatient Glycemic Control

  2009cited by this paper
• Medication Safety: Occurrence and Impact of Unanticipated Variation in Intravenous Methotrexate Dosing

  2006cited by this paper
• Management of diabetes and hyperglycemia in hospitals.

  2004cited by this paper
• Discrepancies between ordered and delivered concentrations of opiate infusions in critical care

  2003cited by this paper
• Perioperative management of diabetes.

  2003cited by this paper
• The hyperinsulinaemic-euglycaemic glucose clamp: reproducibility and metabolic effects of prolonged insulin infusion in healthy subjects.

  2000cited by this paper
• Survey of hospital systems and common serious medication errors.

  1998cited by this paper
• THE EUGLYCAEMIC HYPERINSULINAEMIC CLAMP: AN EVALUATION OF CURRENT METHODOLOGY

  1997cited by this paper
• Observational study of accuracy in compounding i.v. admixtures at five hospitals.

  1997influential reference
• Difference Between the Measured and Ordered Dose of Catecholamine Infusions

  1995cited by this paper
• Hypoglycaemia, the most feared complication of insulin therapy.

  1994cited by this paper
• Glucose clamp technique: a method for quantifying insulin secretion and resistance.

  1979cited by this paper

• Impact of setting distinct target blood glucose levels on endogenous insulin suppression and pharmacodynamics of insulin preparations

  2025cites this paper
• New Insulins, Biosimilars, and Insulin Therapy

  2023cites this paper
• How to Achieve Sufficient Endogenous Insulin Suppression in Euglycemic Clamps Assessing the Pharmacokinetics and Pharmacodynamics of Long-Acting Insulin Preparations Employing Healthy Volunteers

  2022cites this paper
• Pharmacokinetic and pharmacodynamic bioequivalence between regular human insulin (rDNA origin) in 0.9% sodium chloride ready‐to‐use infusion 1 U/mL and 100 U/mL concentrate diluted to 1 U/mL in healthy males

  2021cites this paper